By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue
Suite 100
Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS




Collaborations

AVANIR 





Company News
Peregrine (PPHM) Reports Financial Results For Quarter And Fiscal Year Ended April 30, 2016 And Recent Developments 7/15/2016 8:08:43 AM
Peregrine (PPHM) Licenses Novel Exosome-Based Cancer Detection And Monitoring Technology From UT Southwestern Medical Center 7/14/2016 8:08:05 AM
Peregrine (PPHM) Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC (AZN)’s Durvalumab 6/2/2016 8:09:53 AM
Peregrine (PPHM) Release: Preclinical Data Presented At AACR Annual Meeting Demonstrate Enhanced Therapeutic Benefit Of Combining A Ps-Targeting Antibody With Anti-Pd-1 Therapy In Models Of Triple Negative Breast Cancer (TNBC) 4/20/2016 3:15:37 PM
Peregrine (PPHM) Announces Formal Commissioning Of New, State-Of-The-Art Commercial Manufacturing Facility 3/7/2016 8:27:30 AM
Peregrine (PPHM) Stock Crashes After Company Terminates Phase III Trial for Bavituximab 2/26/2016 6:05:07 AM
Peregrine (PPHM) Provides Update On Planned Expansion Of Bavituximab Clinical Program In Lung, Breast And Other Cancers 1/11/2016 11:38:53 AM
Peregrine (PPHM) And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab 1/6/2016 10:21:11 AM
Peregrine (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 12/8/2015 10:01:23 AM
Peregrine (PPHM) Release: New Preclinical Data Presented At SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors In Breast Cancer And Melanoma 11/9/2015 1:00:37 PM
12345678910...
//-->